Adlai Nortye's Pioneering Cancer Therapy Presentation at Key Conference
Adlai Nortye to Share Breakthrough Cancer Therapy Insights
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China — Adlai Nortye Ltd. (NASDAQ: ANL), a dedicated biotechnology firm engaged in pioneering innovative cancer treatments, recently announced its participation in the prestigious AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
Event Highlights
The significant event is scheduled for October 22-26, 2025, in Boston, where esteemed professionals and stakeholders in the oncology field come together to discuss advancements in cancer therapies.
Presentation Information
During this event, Adlai Nortye will present an oral talk, shedding light on a prominent topic in cutting-edge cancer research. The presentation, titled Discovery of AN4035, will revolve around a novel CEACAM5-targeting antibody drug conjugate (ADC) that is empowered by a proprietary pan-RAS(ON) inhibitor payload. This innovative approach is designed to enhance the therapeutic window for cancer treatment.
Expect the oral presentation to take place on Saturday, October 25, 2025, from 11:45 AM to 12:15 PM ET, under the session titled Spotlight on Proffered Papers 3: Novel Therapeutic Agents. The venue for this enlightening discussion will be Level 3, Ballroom AB, Hynes Convention Center, located in Boston.
Upcoming Insights
Adlai Nortye plans to release a detailed press statement shortly after the public unveiling of the abstract on the AACR portal on October 22, providing insights into the scientific rationale and data highlights regarding drug candidate AN4035.
Innovative Cancer Therapeutics
Adlai Nortye has emerged as a trailblazer in the global cancer therapy landscape, focusing their efforts on an innovative drug development portfolio that spans two critical therapeutic areas. Their research and development operations harness cutting-edge science and an impressive team of experts based in both the U.S. and China.
Key Areas of Focus
The first area of development centers around next-generation PD-1/L1 modulation. Their candidate, AN8025, is a multifaceted fusion protein intended to modulate immune responses by engaging T cells and antigen-presenting cells. In conjunction with this, AN4005 represents a novel first-in-class oral small-molecule PD-L1 inhibitor designed to offer promising outcomes for patients.
Furthermore, Adlai Nortye explores RAS-targeted therapies, including AN9025, an oral pan-RAS(ON) inhibitor that demonstrates the potential to treat a number of RAS-driven cancers. Additionally, the company is advancing its research on the promising AN4035, which aims to connect the innovative technology of antibody-drug conjugates with cutting-edge inhibitors.
Community Engagement and Future Goals
Adlai Nortye is not just driven by clinical results; they also prioritize community engagement and education concerning cancer awareness and therapy advancements. By participating in high-profile conferences such as the AACR-NCI-EORTC, the company illustrates its commitment to fostering dialogue in the oncology community.
Moreover, the company remains focused on bolstering its strategic corporate partnerships. Whether through collaborations or their advancements in drug development, Adlai Nortye's objective is to navigate the complexities of cancer treatment efficiently, ensuring access to innovative therapies for patients in need.
Frequently Asked Questions
What is the main focus of Adlai Nortye Ltd.?
Adlai Nortye Ltd. is a biotechnology company focused on developing innovative cancer therapies.
When will Adlai Nortye present at the AACR-NCI-EORTC conference?
The presentation will occur on October 25, 2025, from 11:45 AM to 12:15 PM ET.
What is AN4035?
AN4035 is a novel CEACAM5-targeting antibody drug conjugate designed with a unique pan-RAS(ON) inhibitor payload.
Where will the conference take place?
The conference will be held at the Hynes Convention Center in Boston, MA.
How is Adlai Nortye contributing to cancer research?
Adlai Nortye is advancing a diverse portfolio of drug candidates targeting key areas in cancer therapy through innovative research and development.
About The Author
Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.